Atossa Therapeutics, Inc.
ATOS
$0.5897
-$0.0304-4.90%
| Weiss Ratings | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.25 | |||
| Price History | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.24% | |||
| 30-Day Total Return | -22.99% | |||
| 60-Day Total Return | -32.21% | |||
| 90-Day Total Return | -54.64% | |||
| Year to Date Total Return | -38.58% | |||
| 1-Year Total Return | -66.68% | |||
| 2-Year Total Return | -20.30% | |||
| 3-Year Total Return | -48.27% | |||
| 5-Year Total Return | -61.71% | |||
| 52-Week High % Change | -67.95% | |||
| 52-Week Low % Change | 6.71% | |||
| Price | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.84 | |||
| 52-Week Low Price | $0.55 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 76.17M | |||
| Enterprise Value | 5.09M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.20 | |||
| Earnings Per Share Growth | -15.09% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.07 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.59 | |||
| Enterprise Value/EBITDA (TTM) | -0.18 | |||
| Enterprise Value/EBIT | -0.18 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 126.61M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 206-588-0256 | |||
| Address | 107 Spring Street Seattle, WA 98104 | |||
| Website | www.atossatherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.99% | |||
| Return on Equity | -- | |||
| Income Statement | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -27.60M | |||
| EBIT (TTM) | -27.62M | |||
| Net Income (TTM) | -25.50M | |||
| Net Income Avl. to Common (TTM) | -25.50M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 18.15% | |||
| EPS Diluted (TTM) | -0.20 | |||
| EPS Diluted Growth (Q YOY) | 19.06% | |||
| Balance Sheet | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 71.08M | |||
| Cash Per Share (Q) | $0.56 | |||
| Total Current Assets (Q) | 74.46M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 71.48M | |||
| Current Ratio (Q) | 14.990 | |||
| Book Value Per Share (Q) | $0.55 | |||
| Total Assets (Q) | 76.44M | |||
| Total Current Liabilities (Q) | 4.97M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 4.97M | |||
| Total Common Equity (Q) | 71.48M | |||
| Cash Flow | ATOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -19.00K | |||
| Cash from Financing (TTM) | 3.67M | |||
| Net Change in Cash (TTM) | -17.38M | |||
| Levered Free Cash Flow (TTM) | -14.86M | |||
| Cash from Operations (TTM) | -21.03M | |||
